MedTrace Logo

Prospective Study of Benznidazole for Chagas' Disease Children With Chronic Indeterminate Chagas Disease

NCT04024163 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 178

Last updated 2026-04-21

No results posted yet for this study

Summary

This study evaluate the efficacy and safety of benznidazole in the treatment of chronic indeterminate Chagas disease in children. All subjects will receive benznidazole and results will be compared to historically to a placebo arm.

Conditions

  • Chagas Disease

Interventions

DRUG

Benznidazole

Drug: Benznidazole Tablets 100 mg (functionally scored) or Tablets 12.5 mg

Sponsors & Collaborators

  • Chemo Research

    collaborator INDUSTRY

  • Insud Pharma

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
2 Years
Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-09-19
Primary Completion
2027-08-30
Completion
2028-03-30
FDA Drug
Yes

Countries

  • Argentina
  • Bolivia
  • Colombia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04024163 on ClinicalTrials.gov